In this edition of the journal, Bruhwiler and Schwappach present results of a survey investigating the implementation of safety measures for vincristine and intrathecal (IT) chemotherapies in Switzerland. 1 Of 21 hospitals who manufactured both parenteral chemotherapy and IT chemotherapy, 16 (76%) still prepared vincristine in syringes mainly in small volumes. The most prevalent safety measures in use were specific labelling for vincristine and special delivery systems for IT medications. They concluded that compliance with international recommendations to ensure the safe use of vincristine were insufficient. These results, particularly coming from an affluent well-educated country, are extremely concerning and disheartening.
In 2004, following the death from an inadvertent IT administration of vincristine in Australia, an editorial was published in the Journal of Oncology Pharmacy Practice (JOPP). 2 In addition to documenting the case, a series of recommendation were made with the aim of preventing further errors like this occurring. The primary strategy suggested was to prepare and administer vincristine in a small volume mini-bag rather than a syringe thus physically preventing the vincristine syringe being accidently attached to a spinal needle. This method had been first proposed in 2003 by two Australian oncology pharmacists and International Society of Oncology Pharmacy Practitioners (ISOPP) members. 3 A further editorial, written after more deaths had occurred and questioning whether anything had changed, was published in 2012. 4 ISOPP, in conjunction with JOPP, has been at the forefront in getting information regarding medication safety with IT administration disseminated to oncology pharmacists around the world. This has been in the hope that pharmacists would take the lead in their own countries to ensure preventative measures, particularly the replacement of the syringe with the mini-bag for vincristine administration, are endorsed and put into clinical use nationally and globally.
To my knowledge there have been at least 135 cases of accidental vincristine IT administration reported, and many more episodes have likely gone unreported. Thirty-five of these cases, with 28 fatalities, have been documented in the medical literature. There have been two reviews of case reports of inadvertent IT administration associated with vincristine, with the last published in 2014. 5, 6 The second article also addressed any potential medication errors that could happen with IT chemotherapy, including overdoses of IT drugs and inadvertent IT administration of drugs other than vincristine. 6 This was published in a leading American cancer nursing journal with the aim of reaching a wide international audience of oncology nurses and hoping that they may be able to assist in driving change. Since 2014, to my knowledge, there have been three further incidents documented, all fatalities. [7] [8] [9] These errors occurred in the USA (Florida), India and Poland.
In the first case, a 59-year-old man with diffuse large B-cell lymphoma inadvertently received vincristine by the IT route. 7 Despite attempts at cerebrospinal lavage he died five days later. A 6-year-old girl with acute lymphoblastic leukaemia in complete remission, was accidently administered vincristine intrathecally instead of methotrexate. 8 She subsequently developed progressive encephalopathy, quadriparesis and respiratory paralysis. After five months of mechanical ventilation she finally expired. A 9-week-old boy with congenital leukaemia was administered IT vincristine accidently and despite immediate recognition of the error and cerebrospinal lavage, progressed to neurologic symptoms after five days. The baby died after 115 days of hospitalisation. The author of the final case attempted to analyse the reasons for committing this error.
She listed several factors but failed to recognise that vincristine was supplied in a syringe. Literature recommendations were cited, including the information that vincristine should be contained in a mini-bag. However, administration in a 50 mL syringe was offered as an alternative to the mini-bag.
The misapprehension that extravasation risk was higher when vincristine was manufactured in a minibag than when supplied in a syringe was commonly nominated as the major reason for not instituting the change to mini-bags. A retrospective study of documented cases from 68 Australian hospitals examined the incidence of extravasation of vincristine after administration via syringes and small volume minibag infusions. 10 The frequency of vincristine extravasation was rare and similar from both methods (0.03% from syringes and 0.041% from mini-bags). In 2013, a survey of the ISOPP membership received 62 responses from 15 countries. 11 Syringes were still being used in 31.1% of centres, with half of those doses being prepared undiluted. The most common reasons for using syringes were the perceived lesser risk of extravasation and the faster administration time. Despite numerous vincristine administrations, extravasation was rarely seen. Nurgat et al. conducted a study in Saudi Arabia to establish the incidence of vincristine extravasation administered in mini-bags in paediatric and adult patients. 12 There were no reported cases of extravasation from 421 occasions of vincristine administration in 25 mL or 50 mL mini-bags. When correct techniques for antineoplastic drug administration are followed, extravasation occurs infrequently (<1 per 1000 IV administrations) and the consequences are significantly less than those associated with the accidental IT administration of vincristine. 13 In September 2019, ISOPP, in conjunction with the International Medication Safety Network (ISMN), conducted an international webinar which addressed issues concerning medication safety in an oncology environment. This educational activity placed particular emphasis on the prevention of accidental IT administration of vincristine. One of the initiatives discussed was the 2012 ISMP International Medication Safety Self-Assessment V R for Oncology which was developed by the Institute for Safe Medication Practices (ISMP) and the Institute for Safe Medication Practices Canada (ISMP Canada), through a grant from ISOPP to help hospitals and ambulatory care centres throughout the world evaluate oncology medication safety. 14 Chemotherapy and biotherapy agents used in cancer treatment are considered to be 'high-alert' drugs which are more likely to cause patient harm when involved in an error. The self-assessment is designed to heighten awareness of the distinguishing characteristics of a safe medication system, with a specific focus on management of chemotherapy, biotherapy, and treatment-related drugs. The assessment includes four questions relating to vincristine including the following -'VinCRIStine is dispensed in a mini-bag of a compatible solution (e.g., 25 mL for paediatric patients and 50 mL for adults). VinCRIStine doses are never dispensed and/or administered using a syringe'. A total of 352 organizations from 13 countries submitted assessment results. Key opportunities for improvement were identified in five areas, including the implementation of the World Health Organization recommendations for management of vincristine and other vinca alkaloids. 14 While 61.1% (215/352) of respondents from all countries indicated that the safeguard of administering vincristine via a mini-bag was fully in place for their practice setting, regional variations in responses were noted with Australia and New Zealand having the highest rate of full implementation. Concerningly, of the 45.8% (124/271) of US respondents reporting that they did not always supply vincristine in mini-bags, 35.4% (96/271) indicated that this strategy had either not been discussed or had been formally discussed but not implemented. A prospective, system-focused clinical risk assessment using Healthcare Failure Mode Effect Analysis (HFMEA) was applied on the vincristine use process in the out-patient and in-patient oncology units of the major teaching and referral hospital in Kenya and has recently been published online in JOPP. 15 Prior to the analysis vincristine was either dispensed in vials for preparation or in small-volume syringes for administration with other medications including IT drugs. The process was sub-divided into five phases: (i) prescribing, (ii) preparation and dispensing, (iii) transportation, (iv) storage and (v) administration and monitoring. Seventy-seven failure modes were identified, of which 25 were classified as high risk. One of these was the use of small volume syringes that can be confused for IT route use. To fix the problem the following recommendation was made. Dilute vincristine with 0.9% normal saline using large volume syringes: for paediatrics less than 10 years use 10 mL syringes, if more than 10 years, 20 mL or 20 mL mini-bags for paediatrics and 50 mL mini-bags for adults. 15 While I applaud their initiative in conducting this analysis, this recommendation is totally inadequate and fails to recognise that deaths have still occurred with 10 mL and 20 mL syringes. 16, 17 After contacting the authors, I have discovered that the hospital did not have access to mini-bags at the time of the study but have now been able to purchase 100 mL bottles. Hopefully excess volume can be removed from these bottles or smaller mini-bags obtained to allow all patients to receive vincristine via a mini-bag and never a syringe. Access to small volume mini-bags also seems to be a problem in other countries.
The campaign to abolish the syringe as a method for vinca alkaloid administration is reminiscent of the continuing call for gun control measures in the USA, though hopefully not as hard to achieve (Figure 1) . Following a mass shooting in 1996, the Australian government introduced very strict gun control laws, including the banning of automatic weapons, despite complaints from farmers and sporting shooters. Since then there has only been one mass shooting, which occurred with a non-automatic weapon, in over 20 years. In the USA, a country with virtually no gun control legislation, there seems to be a mass shooting on an almost daily basis. Similarly, after the 2004 death from IT vincristine, Australia was quick to embrace the abolishment of the syringe, despite some initial reluctance from nursing groups who had concerns regarding the risk of extravasation. No incidents have occurred in Australia since. In many countries there has been a lack of progress in banning the syringe for vincristine administration and, not surprisingly, unnecessary deaths have continued to occur.
Several years ago, I received an email from a woman in Argentina. Her young niece had been inadvertently given vincristine intrathecally while undergoing treatment for leukaemia. She had found my details while conducting a Google V R search and had contacted me in the hope that I could provide information on treatments to reverse the neurological consequences. It was heart-breaking that I was not able to help and had to explain that my expertise was in medication error prevention not treatment. The only assistance I could provide was to send journal articles on what management strategies had been tried to the paediatrician who was caring for the child after the tragic mistake. This tragedy has further steeled my resolve to continue advocating for the abolishment of the syringe.
In now, my third editorial in JOPP on this topic, I must again quote the final sentences from the two previous editorials in the hope that we, as oncology pharmacy practitioners, can lead the way and finally win the battle to abolish the syringe as a method of administering vincristine and other vinca alkaloids. Unless we, as oncology pharmacists, work together to ensure vincristine can only be given intravenously it is only a matter of time until another tragic fatality occurs. 2 Please do not allow the accidental administration of vincristine by the IT route to ever occur again. 4 
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